12:00 AM
 | 
Dec 16, 2013
 |  BC Week In Review  |  Company News  |  Deals

Aptalis Pharma, NovaMedica deal

Aptalis granted NovaMedica exclusive rights to develop and commercialize three of Aptalis' gastrointestinal products - Pylera, Lacteol and Panzytrat - in Russia. NovaMedica will complete requirements to obtain regulatory approval in Russia. NovaMedica expects to launch...

Read the full 168 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >